Neuren Pharmaceuticals Limited (ASX: NEU)
Health Care · Pharmaceuticals · AU
AU$22.46
-4.22% today · +27.2% 1Y
Neuren Pharmaceuticals Limited (ASX: NEU) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.04B and employs 9 people.
Over the last twelve months the share price has gained 27.2%, trading between 11.00 and 23.76.
Tweenvest scores Neuren Pharmaceuticals Limited across four factors: quality 67/100, value 16/100. Its strongest factor is quality.
NEU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.04B
- Revenue (TTM)
- $43.12M
- P/E
- 96.52
- EPS
- 0.23
- Dividend yield
- —
- Beta (5Y)
- 1.59
- 52-week high
- AU$23.76
- 52-week low
- AU$11.00
- Avg volume (3M)
- —
- Shares outstanding
- 126.77M
- Employees
- 9
- Next earnings
- —
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
- ISIN
- NZNEUE0001S8
- Founded
- 2001
- Listed since
- Feb 1, 2005
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.